Abiopharma

News list

(90% Positive) Global Blood Therapeutics, Inc. (GBT) Provides Update on Hemolytic Anemia in Patients for Sickle

Full text

News bot Oct. 2, 2025, 4:02 p.m.
📋 Global Blood Therapeutics, Inc. (GBT) - Clinical Trial Update

Filing Date: 2022-07-26

Accepted: 2022-07-26 06:00:22

Event Type: Clinical Trial Update
Event Details:
Global Blood Therapeutics Inc (the company became a subdivision of the company Pfizer Inc (PFE)) (GBT) Announces Clinical Trial Update Global Blood Therapeutics Inc (the company became a subdivision of the company Pfizer Inc (PFE)) (GBT) provided an update on its clinical development programs. Clinical Development Highlights:
Drug Program: Hemolytic Anemia in Patients, people
Diseases/Conditions: Sickle
Collaboration: SCD
💼 Business Developments:
- Partnership
- Acquisition: Not available
- Licensing: Not available
- Regulatory Approval
- Executive Changes: Not available
Structured Data:
- Company Name: Global Blood Therapeutics Inc (the company became a subdivision of the company Pfizer Inc (PFE))
- CIK: 0001629137
- Ticker Symbol: GBT
- Period End Date: 2022-07-26
- Document Type: 8-K